USMJ Reports 12% Revenue Growth With $225,000 In Sales For The Period Ended September 30th 2018

Dallas, TX -- November 20, 2018 -- InvestorsHub NewsWire -- North American Cannabis Holdings, Inc. (USOTC: USMJ) (“USMJ”) today announced filing its first quarter financial report for the period ended September 30^th, 2018.   The company reported $225,000 in revenue compared to $201,000 in revenue for the same period last year.  Management attributes the 12% increase in revenue to organic growth.

USMJ recently announced a series of transactions and events amounting to a business restructuring to ultimately result in USMJ evolving into an online, cannabis sector ecommerce business.  USMJ has published a presentation on the company’s website to detail the recently announced spinoff of its AmeriCanna Cafe business in a transaction with Priority Aviation (USOTC: PJET) (“PJET”).  The presentation includes details on AmeriCanna Cafe’s partnership with West Coast Venture Group (OTCQB: WCVC) (“WCVC”) the owner and operator of the $3 million Colorado based Illegal Burger chain.  More information is already available online regarding the related sale of PJET’s Telluride Health Company to Puration, Inc. (USOTC: PURA) (“PURA”) at https://www.purationinc.com/thc.  The online presentation is available on the company’s website at https://www.growusmj.com/usmjpjetwcvc-presentation.

Learn more about USMJ at www.growusmj.com

Disclaimer/Safe Harbor: 
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. 

Steven Rash
CEO North American Cannabis Holdings, Inc.
[e-mail]
[phone]